Key result
Neoadjuvant MAP chemotherapy resulted in extensive (>95%) tumor necrosis and almost complete resolution of metastases in an 18-year-old male with primary pleomorphic liposarcoma of bone.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Neoadjuvant MAP chemotherapy can induce significant tumor necrosis and clinical response in rare primary pleomorphic liposarcoma of bone.
BACKGROUND: Liposarcoma is an extremely rare primary bone sarcoma. CASE PRESENTATION: We report a case of primary pleomorphic liposarcoma that arose in an 18 year old male in the metaphysis of the left tibia. Plain radiographs showed a partly sclerotic lesion and MR imaging a heterogeneous tumour predominantly isointense on T1- and high-signal on T2-weighted sequences with focal areas of increased T1 signal that suppressed with fat saturation. PET/CT showed marked FDG uptake (SUV = 17.1) in the primary tumour as well as a metastasis in the right distal femur and multiple small pulmonary metastases. Histologically, the tumour was a pleomorphic liposarcoma containing large tumour cells with vacuolated cytoplasm and hyperchromatic pleomorphic nuclei as well as numerous lipoblasts and scattered brown fat-like cells. Tumour cells strongly expressed FABP4/aP2, a marker of adipocyte differentiation, and UCP1, a marker of brown fat, but not S100. The case was treated with neoadjuvant MAP chemotherapy, resulting in extensive (> 95%) necrosis in the primary tumour and almost complete resolution of the femoral and pulmonary metastases. CONCLUSIONS: Pleomorphic liposarcoma can present as a sclerotic primary malignant bone tumour; markers of adipose differentiation are useful in histological diagnosis and neoadjuvant MAP chemotherapy results in significant tumor necrosis.
No takes yet. Share an insight, caveat, or question.
Tiemeier et al. (2018) conducted a case report in Primary pleomorphic liposarcoma of bone (n=1). Neoadjuvant MAP chemotherapy and surgical resection was evaluated on Tumor necrosis and clinical response. Neoadjuvant MAP chemotherapy resulted in extensive (>95%) tumor necrosis and almost complete resolution of metastases in an 18-year-old male with primary pleomorphic liposarcoma of bone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: